Class Notes
Class Notes | Obituaries
Submit a Class Note or Obituary »
Showing class notes submitted in the last month by graduates in the 1980s
1980
Charles "Chuck" Berger MBA ’80 is the new president and CEO of Extreme Networks, a tech company. He's also been elected to the board of directors.
Berger is joining Extreme Networks following the successful sale of ParAccel, a privately held software analytics company to Actian. He is an established CEO and director with 30 years of experience in the technology sector, including extensive P&L, general management, marketing and financing experience in high growth, large and mid-sized companies. Prior to ParAccel, Berger served as the CEO of DVDPlay, Nuance Communications, Vicinity Corporation, AdForce, and Radius. He has also held executive positions in sales, marketing and finance at Apple and Sun Microsystems.
1985
David Drummond ’85, Google’s chief legal officer, will speak at the SCU law school commencement on May 25.
1988
Dr. Jimmy Roehrig M.S. ’88 has joined Matakina International, a leader in the development of objective volumetric measurement of breast density. Roehrig will provide scientific depth to the U.S. sales effort and strategic planning for product development and intellectual property, particularly with the software Volpara, designed to help overcome the limitations of mammography to detect cancer in women with dense breasts; it generates objective, automatic measurement of volumetric breast density values along with a BI-RADS Breast Density Classification for mammograms acquired from any commercially available digital mammography system.
Roehrig, who co-founded R2 Technology, served as chief science officer and was responsible for building the technical team that produced the ImageChecker® computer-aided detection (CAD) system, the first CAD system approved by the FDA. As VP of Advanced Development, Dr. Roehrig led the development and refinement of R2’s proprietary algorithm for the earlier detection of breast cancer and managed efforts to apply the technology to other diseases. Upon the acquisition of R2 by Hologic, Inc, Dr. Roehrig remained until 2012, working primarily in the field of quantitative DCE MRI for breast imaging.
